CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.0751
-0.0080 (-9.63%)
At close: Nov 4, 2024, 4:00 PM
0.0767
+0.0016 (2.13%)
After-hours: Nov 4, 2024, 7:29 PM EST
CERO Employees
As of December 31, 2023, CERo Therapeutics Holdings had 9 total employees, including 8 full-time and 1 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$305,972
Market Cap
11.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 142 |
| Cosmos Health | 123 |
| Vivos Therapeutics | 123 |
| ImmunoPrecise Antibodies | 101 |
| STRATA Skin Sciences | 99 |
| BiomX | 71 |
| Biora Therapeutics | 58 |
| Sensei Biotherapeutics | 28 |
CERO News
- 14 days ago - CERo Therapeutics, Inc. Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer - GlobeNewsWire
- 5 weeks ago - Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump - Benzinga
- 5 weeks ago - CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 - GlobeNewsWire
- 3 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 5 months ago - CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 - GlobeNewsWire
- 6 months ago - CERo Therapeutics, Inc. Provides Corporate Update for Shareholders - GlobeNewsWire
- 8 months ago - CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients - Business Wire